Clinical-stage biotechnology company developing life-changing gene therapy products for musculoskeletal diseases
Genascence has raised $11.6M in total funding. The most recent round was Grant. The last funding was announced in February 2023.
Genascence's investors include DeepWork Capital, Pacira Pharmaceuticals, California Institute for Regenerative Medicine, University of Florida Research Foundation, Polymerase Capital.
Genascence is headquartered in Palo Alto, United States.
Clinical-stage biotechnology company developing life-changing gene therapy products for musculoskeletal diseases
Genascence is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Genascence — Funding & Investors." VCBacked, February 23, 2023, https://www.vcbacked.co/company/genascence. Accessed August 13, 2026.
VCBacked. (2023). Genascence — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/genascence
{{cite web |title=Genascence — Funding & Investors |url=https://www.vcbacked.co/company/genascence |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated